Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.65 SEK | +0.53% | +3.00% | -7.07% |
25/04 | Swedencare AB Approves Dividend for the Year 2023, Payable on May 3, 2024 | CI |
25/04 | Transcript : Swedencare AB, Q1 2024 Earnings Call, Apr 25, 2024 |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 39.47 and 26.22 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.76 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.07% | 832M | D+ | ||
-15.35% | 76.34B | B+ | ||
-9.19% | 6.67B | B- | ||
+24.75% | 3.7B | B- | ||
-1.11% | 3.21B | B- | ||
+6.08% | 1.52B | - | ||
-15.13% | 1.37B | B | ||
-25.63% | 1.24B | C- | ||
-7.62% | 1.21B | - | ||
-10.84% | 1.17B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SECARE Stock
- Ratings Swedencare AB